LEXINGTON, Mass.--(BUSINESS WIRE)--June 22, 2006--Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV - News) today reported that it has completed the enrollment of its pharmacokinetic trial for NEBIDO, the Company's long-acting injectable testosterone preparation for the treatment of male hypogonadism.
